Role of serum fibroblast growth factor-23 and Klotho level in COVID-19 infection-related mortality: a prospective

Davut Akin1, Burcu B Aydogan2, Nilufer Emre3

  • 1Department of Nephrology, Pamukkale University School of Medicine, Denizli,Turkey.

Insights

Elevated fibroblast growth factor 23 (FGF23) and lower Klotho levels are linked to higher mortality in hospitalized COVID-19 patients without chronic kidney disease. These biomarkers, along with age and oxygen saturation, predict mortality risk.

Area of Science:

  • Biochemistry and Molecular Biology
  • Infectious Diseases
  • Nephrology

Background:

  • Investigated the role of fibroblast growth factor 23 (FGF23)/Klotho in COVID-19 mortality.
  • Excluded patients with chronic kidney disease (CKD).

Purpose of the Study:

  • To determine the association between FGF23/Klotho levels and mortality in hospitalized COVID-19 patients without CKD.
  • To identify independent predictors of mortality in this patient cohort.

Main Methods:

  • Prospective cross-sectional study from April 2021 to May 2022.
  • Classified 66 COVID-19 patients into survivors and non-survivors.
  • Analyzed demographic data, clinical status, prognosis, and serum biomarkers including FGF23, Klotho, and Vitamin D.

Main Results:

  • Non-survivors were significantly older and had higher FGF23 levels compared to survivors.
  • Elevated FGF23, older age, and lower oxygen saturation at admission were independent predictors of mortality.
  • Lower Klotho levels were observed in non-survivors, while Vitamin D levels showed no significant difference.

Conclusions:

  • Elevated serum FGF23 and lower Klotho levels are associated with COVID-19-related mortality in patients without CKD.
  • Serum Vitamin D levels were not associated with mortality in this cohort.
  • Further research is needed to elucidate the complex relationships between FGF23/Klotho, PTH, Vitamin D, and COVID-19 mortality.
Abstract